About Alnylam Pharmaceuticals

Since its founding 20 years ago, Alnylam has led the translation of RNA interference (RNAi) into a new class of approved and investigational medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics are a clinically validated approach for the treatment of rare diseases with unmet medical need and prevalent diseases. Alnylam is headquartered in Cambridge, MA. For more information, please visit www.alnylam.com.

Resources are intended for US Healthcare Professionals only. For additional information about hATTR amyloidosis, please see the resources available to the right or at www.hattramyloidosis.com.

This virtual exhibit booth is not part the curriculum of an accredited education program and no CME credits are offered for reviewing this page.

© 2023 Alnylam Pharmaceuticals, Inc. All rights reserved.

PDF icon hATTR Amyloidosis Disease Awareness Visual Aid

PDF icon hATTR Amyloidosis Red Flag Symptom Tool

Contact Information:

Monica Ammerman
Business Account Executive
Alnylam Pharmaceuticals
(701) 388-0867